Brussels (Belgium), 17 May 2019 The appointment follows the EUR 37m Series A round and supports the next growth stage The Board now consists of Christina Takke (Chair), Karl Nägler, Mårten Steen, Morten Graugaard Døssing, Ohad Hammer, Jean-Louis Baudhuin, Thomas Ramdah... read more

May 16, 2019 - Regulatory press release Press releases Stockholm – May 16, 2019 – Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that a total of four abstracts have been accepted for presentation at the 24th Congress of European Hematology Association (EHA) meeting (Ju... read more

May 15, 2019 - Regulatory press release Press releases Stockholm – May 15, 2019 – Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that data from its Phase 1/2 O-12-M1 study evaluating melflufen, a lipophilic peptide-conjugated alkylator belonging to the novel class of p... read more

15 May 2019 Press releases Durable improvement in best-corrected visual acuity (BCVA), as GS010-treated eyes sustain +15.4 ETDRS letters equivalent improvement versus baseline and +28.1 ETDRS letters equivalent versus nadir Bilateral improvement continues in key visual... read more

May 14, 2019 at 4:15 PM EDT Conference Call & Webcast Scheduled for Wednesday, May 15, at 8:30am Eastern Time GAITHERSBURG, Md., May 14, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc.(Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced financial results for the ... read more